Skip to main content
Adam Kittai, MD, Hematology, New York, NY

AdamScottKittaiMDMD(He/Him)

Hematology New York, NY

Hematologic Oncology

Assistant Professor

Dr. Kittai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kittai's full profile

Already have an account?

  • Office

    1425 Madison Avenue
    New York, NY 10029

Education & Training

  • Oregon Health & Science University (OHSU Health)
    Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2016 - 2019
  • George Washington University
    George Washington UniversityChief Residency, Internal Medicine, 2015 - 2016
  • George Washington University
    George Washington UniversityResidency, Internal Medicine, 2012 - 2015
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 2012

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2023 - 2025
  • OH State Medical License
    OH State Medical License 2019 - 2024
  • OR State Medical License
    OR State Medical License 2016 - 2021
  • DC State Medical License
    DC State Medical License 2015 - 2016
  • VA State Medical License
    VA State Medical License 2012 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies
    Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
    Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
    Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJuly 30th, 2024
  • Efficacy of New Agents, CAR-T Insights Among EHA 2024 Highlights in CLL
    Efficacy of New Agents, CAR-T Insights Among EHA 2024 Highlights in CLLJuly 12th, 2024
  • BTK Degrader Shows Potential for Treating Refractory CLL and SLL
    BTK Degrader Shows Potential for Treating Refractory CLL and SLLFebruary 8th, 2023
  • Join now to see all

Professional Memberships